Is Psoriasis Genetic? What Your DNA Really Tells You — and What It Doesn't

When psoriasis appears in a family, one of the first questions everyone asks is: Will others get it too? If you have just been diagnosed, you may be wondering whether your parents are responsible, whether your children are at risk, or whether your genes have essentially sealed your fate. The honest, science-based answer is: yes, psoriasis is partly genetic - but genetics is only one piece of a more complex picture.

This article breaks down exactly how genetics contributes to psoriasis, which specific genes are involved, what twin studies and family research actually show, how genetic risk is inherited, and — critically — why having psoriasis genes does not mean psoriasis is inevitable. It also explains what this means for treatment and for the lifestyle choices that can genuinely shift disease outcomes.

The Short Answer: Yes, Psoriasis Has a Strong Genetic Component

Psoriasis is one of the most genetically influenced skin conditions in medicine. Decades of research — including family studies, twin studies, and large-scale genome-wide association studies (GWAS) — have confirmed beyond any doubt that genetic factors play a major role in determining who develops psoriasis. Estimates suggest that genetic factors account for approximately 60–70% of an individual's overall risk.

However, psoriasis is not a purely genetic disease in the way that, say, Huntington's disease or cystic fibrosis is. It does not follow a simple dominant or recessive inheritance pattern, and most people who carry psoriasis-associated genes never develop the condition in their lifetime. Psoriasis is a multifactorial, polygenic disease — meaning many genes each contribute a small effect, and environmental and lifestyle triggers must also be present for the disease to manifest.

What the genetics of psoriasis tells us — key points: • Psoriasis is polygenic: 80+ genetic loci are associated with psoriasis risk • Genetic factors account for approximately 60–70% of overall disease risk • No single gene causes psoriasis — multiple genes each contribute small effects • If one parent has psoriasis, a child has ~10% risk of developing it • If both parents have psoriasis, that risk rises to 40–70% • Identical (monozygotic) twins have 35–70% concordance — confirming environment also matters • You can carry psoriasis genes your entire life and never develop the condition

What Family and Twin Studies Tell Us About Psoriasis Genetics

Before the era of genetic sequencing, scientists studied families and twins to understand how much of psoriasis risk is inherited. These studies remain some of the most informative evidence we have on the genetic architecture of the condition — and they tell a nuanced story.

Family Studies: Psoriasis Runs in Families — But Not Always

The hereditary nature of psoriasis is well-documented in family aggregation studies — research that maps how frequently psoriasis occurs across multiple generations of the same family. People with a first-degree relative (parent, sibling, or child) with psoriasis have a two- to three-fold higher risk of developing the condition compared to the general population. When both parents are affected, the risk for each child rises dramatically — from roughly 10% with one affected parent to 40–70% with two.

Yet perhaps more striking is what family studies also reveal: psoriasis frequently skips generations. A grandparent and grandchild may both have psoriasis while the parent in between does not. Siblings with identical genetic material from the same parents may have very different psoriasis outcomes. These patterns confirm that genetic risk is necessary but not sufficient — it must be activated by other factors to produce disease.

Twin Studies: The Most Powerful Evidence

Twin studies are the gold standard for separating genetic from environmental influences in disease. By comparing the rate at which both members of a twin pair develop the same condition, scientists can estimate the relative contributions of genes and environment. If a condition were purely genetic, identical twins (who share 100% of their DNA) would always both develop it. If it were purely environmental, identical and fraternal twins (who share 50% of DNA) would have the same concordance rate.

In psoriasis, identical (monozygotic) twins show a concordance rate of approximately 35–70% — meaning that when one identical twin has psoriasis, the other twin has it too in roughly 35–70% of cases. Fraternal (dizygotic) twins, who share only 50% of their DNA, have a concordance rate of approximately 12–20%. The gap between these rates confirms a strong genetic contribution. But the fact that even identical twins are discordant in 30–65% of cases is equally important — it proves that genes alone do not determine psoriasis outcome.

What Discordant Twins Teach Us

When identical twins have different psoriasis outcomes despite sharing all their DNA, the explanation must lie in non-genetic factors — environmental exposures, lifestyle choices, the microbiome, infections, stress, and epigenetic modifications (changes in how genes are expressed without altering the underlying DNA sequence). Discordant identical twins are an invaluable research resource, and studies comparing them have identified specific environmental and epigenetic differences that may explain why the genetically identical twin without psoriasis remained disease-free.

This evidence has profound practical implications. It means that even if you have inherited every psoriasis-associated genetic variant your parent carries, the choices you make — about diet, stress, smoking, alcohol, skin care, and how early you treat infections — can genuinely influence whether and how severely psoriasis develops.

The Specific Genes Linked to Psoriasis

Genome-wide association studies (GWAS) — research designs that scan the entire human genome across thousands of participants to identify variants associated with a disease — have now identified more than 80 genetic loci linked to psoriasis susceptibility. Each of these loci contains one or more genes that influence immune function, skin barrier integrity, or inflammation in ways relevant to psoriasis.

PSORS1: The Strongest Single Genetic Risk Factor

The PSORS1 (Psoriasis Susceptibility 1) locus, located on chromosome 6p21.3 within the major histocompatibility complex (MHC) region, accounts for approximately 35–50% of the heritable risk for psoriasis. It is the single most important genetic determinant of psoriasis identified to date. Within this region, the HLA-Cw6 allele — a specific variant of the human leukocyte antigen gene HLA-C — is the most strongly associated genetic marker for early-onset psoriasis.

HLA-Cw6 is present in approximately 60–65% of people with early-onset plaque psoriasis (onset before age 40), compared to around 10–15% of the general population — making it a highly significant risk factor. People who carry HLA-Cw6 tend to develop psoriasis earlier in life, are more likely to have guttate psoriasis triggered by streptococcal infection, and often have a stronger family history of the condition.

What HLA-Cw6 Actually Does

HLA genes encode proteins expressed on the surface of cells throughout the body. These proteins act as molecular 'identity tags' — they present fragments of proteins from inside cells to T-lymphocytes, allowing T-cells to distinguish self (healthy tissue) from non-self (pathogens or damaged cells). The HLA-Cw6 variant presents self-peptides in a way that is more likely to activate T-cells inappropriately — specifically Th1 and Th17 cells that drive psoriatic inflammation.

This molecular link between HLA-Cw6 and T-cell dysregulation in psoriasis is one of the clearest demonstrations of how genetic risk translates directly into immunological dysfunction — and ultimately into the skin changes that characterise the condition.

IL-23 Pathway Genes: The Th17 Connection

After PSORS1, the next most significant genetic risk factors for psoriasis involve genes in the IL-23/Th17 inflammatory pathway — the signalling cascade now understood to be the central driver of psoriatic skin inflammation. Key variants include IL23R (which encodes the receptor for IL-23 on T-cells and innate immune cells), IL12B (which encodes a subunit shared by both IL-12 and IL-23), and TRAF3IP2 (also known as ACT1, a downstream signalling molecule in the IL-17 pathway).

The genetic amplification of IL-23/Th17 signalling in psoriasis patients is precisely why biologics targeting IL-23 (guselkumab, risankizumab) and IL-17 (secukinumab, ixekizumab) are so extraordinarily effective — they interrupt pathways that are genetically overactivated in affected individuals. In a very real sense, these treatments are personalised medicine guided by genetic understanding.

TNF-alpha Pathway Genes

Several genetic variants associated with psoriasis affect the regulation of TNF-alpha (tumour necrosis factor-alpha), a master pro-inflammatory cytokine. These include TNFAIP3 (which encodes a negative regulator of TNF signalling called A20) and TNIP1 (which encodes a protein that inhibits NF-kB activation). Loss-of-function variants in these regulatory genes allow TNF-alpha signalling to be more sustained and intense than in unaffected individuals — a genetic predisposition to amplified inflammation.

Skin Barrier Genes

More recent GWAS research has identified psoriasis risk variants in genes involved in the skin's epidermal barrier function — including LCE3B and LCE3C (late cornified envelope genes that contribute to the final stages of keratinocyte differentiation and skin barrier formation). Defects in these genes may allow environmental triggers and antigens to penetrate the skin more easily, initiating the immune responses that drive psoriasis. This finding connects psoriasis genetically to other barrier-dysfunction conditions including eczema, though the specific genes and pathways involved differ.

Other Significant Genetic Loci

Beyond these major categories, GWAS have identified risk variants in genes involved in T-cell signalling (RUNX3, TYK2), JAK-STAT pathway regulation (STAT3, JAK2), natural killer cell function (ERAP1, which processes peptides for MHC presentation), and autophagy (ATG16L1). The breadth of genetic loci implicated in psoriasis reflects the disease's biological complexity and explains why individual patients respond differently to different treatments.

How Psoriasis Is Inherited: What Patterns to Expect

Understanding the inheritance pattern of psoriasis helps families interpret their own history and risk more accurately. The picture is more nuanced than a simple dominant or recessive gene — but there are clear, evidence-based patterns that inform risk assessments.

Psoriasis Is Polygenic and Multifactorial

Psoriasis does not follow Mendelian inheritance — it is not caused by a single gene mutation that is either dominant or recessive. Instead, it is polygenic (many genes each contribute small amounts to overall risk) and multifactorial (non-genetic factors, including environment, immune triggers, and lifestyle, are also required). This means there is no single 'psoriasis gene' to test for, and no genetic test currently available can definitively predict whether an individual will develop psoriasis.

What genetic risk means in practice is a lowered threshold — people with more psoriasis-associated genetic variants need less environmental provocation to trigger the immune dysregulation that produces psoriasis. Someone with a high genetic load may develop psoriasis after a mild stressor that would cause no skin symptoms in someone without that genetic background.

Risk by Family Relationship

Research has produced fairly consistent estimates of psoriasis risk based on family history:

•       No family history: approximately 2–3% lifetime risk (general population prevalence)

•       One first-degree relative (parent or sibling) affected: approximately 8–12% lifetime risk

•       Two first-degree relatives affected: approximately 30–40% lifetime risk

•       Both parents affected: approximately 40–70% lifetime risk

•       Identical twin with psoriasis: approximately 35–70% lifetime risk

These figures represent averages across large populations — individual risk depends on which specific genetic variants are involved, environmental history, and a range of other biological factors. They are useful for understanding relative risk, not for making definitive individual predictions.

Early-Onset vs Late-Onset Psoriasis and Genetics

Psoriasis is clinically divided into two subtypes based on age of onset, and the two subtypes have different genetic profiles. Type I psoriasis (early-onset, before age 40) has a stronger genetic basis — it is more strongly associated with HLA-Cw6, more likely to be severe, and more likely to have a positive family history. Type II psoriasis (late-onset, after age 40) is less strongly linked to HLA-Cw6, tends to be milder, and often appears without an obvious family history. This distinction is not absolute, but it helps explain why some people develop severe, early psoriasis despite few obvious environmental triggers, while others develop a milder form later in life.

Why Psoriasis Skips Generations

Parents frequently ask why their child has psoriasis when they themselves do not. The explanation lies in the polygenic nature of psoriasis inheritance. Each parent contributes genetic variants through their own genes, and the combination of variants that ends up in a child can create a higher-risk genetic profile than either parent carries individually. Conversely, a child may inherit the low-risk variants from each parent, avoiding the high-risk combination. Additionally, since many gene variants are involved, the 'right' combination of risk variants may not come together in every generation — explaining why psoriasis appears to skip generations in some families.

Epigenetics: How Environment Changes How Your Genes Behave

One of the most important developments in psoriasis research over the last decade is the understanding that genes do not operate in a vacuum. Epigenetic modifications — changes in how genes are expressed without altering the underlying DNA sequence itself — are emerging as a crucial bridge between genetic predisposition and actual disease development.

What Epigenetics Means in Practice

Think of your DNA as a script and epigenetics as the director's instructions — which lines are spoken loudly, which are whispered, and which are never performed at all. Environmental exposures — smoking, diet, stress, pollution, infections — can alter these epigenetic marks (DNA methylation, histone modification, non-coding RNA expression) in ways that turn inflammatory genes on or off. In psoriasis, epigenetic studies have found altered methylation patterns in key immune and inflammatory gene promoters in psoriatic skin compared to healthy skin.

The clinical implication is significant: epigenetic changes can be partially reversible. Lifestyle interventions — quitting smoking, dietary changes, stress reduction — can modify epigenetic marks and shift the expression of inflammatory genes in beneficial directions. This is part of the biological explanation for why lifestyle changes have measurable effects on psoriasis severity even in patients with strong genetic predisposition.

Stress and Epigenetics in Psoriasis

Psychological stress produces epigenetic changes — particularly in genes governing cortisol production and immune regulation. Chronic stress has been shown to alter the methylation of glucocorticoid receptor genes, reducing the immune system's sensitivity to cortisol (which normally has anti-inflammatory effects). In people with psoriasis-susceptibility genes, this stress-induced epigenetic shift can lower the threshold for immune dysregulation, triggering or worsening disease. This is one of the clearest mechanistic explanations for why stress is such a powerful psoriasis trigger.

Smoking, Alcohol, and Epigenetics

Tobacco smoke contains compounds that directly modify DNA methylation patterns and histone marks in immune cells, promoting pro-inflammatory gene expression. Studies of psoriasis patients who smoke versus non-smokers have found significantly different epigenetic profiles in peripheral blood immune cells — profiles that align with the more severe and treatment-resistant disease typically seen in smokers. Alcohol similarly promotes epigenetic pro-inflammatory changes, partly through its metabolite acetaldehyde, which directly interferes with DNA methylation enzymes.

Genetics and Psoriasis Comorbidities: Why the Same Genes Drive Multiple Conditions

Psoriasis-associated genetic variants do not only influence skin inflammation — they affect immune regulation more broadly, which explains why people with psoriasis have elevated rates of several seemingly unrelated conditions. Understanding the genetic overlap between psoriasis and its comorbidities is important for comprehensive health management.

Psoriatic Arthritis: Shared Genetic Architecture

Psoriatic arthritis — the inflammatory joint condition that develops in 20–30% of psoriasis patients — shares many of the same genetic risk factors as psoriasis, including HLA-Cw6, IL-23R variants, and TNFAIP3. However, psoriatic arthritis also has additional genetic risk factors including HLA-B27 (more commonly associated with axial or spinal involvement) and IL-13. Nail psoriasis is the clinical feature most strongly predictive of psoriatic arthritis development, and patients with nail involvement should be monitored closely for joint symptoms regardless of genetic testing.

Inflammatory Bowel Disease: The IL-23 Link

The genetic overlap between psoriasis and inflammatory bowel disease (Crohn's disease and ulcerative colitis) is substantial — they share risk variants at the IL23R, IL12B, and TNFAIP3 loci, among others. This explains the elevated rates of IBD in psoriasis patients and the remarkable efficacy of biologics targeting the IL-23 pathway in both conditions. Patients with psoriasis and gastrointestinal symptoms should not dismiss the possibility of underlying IBD — both conditions reflect the same underlying immune genetic predisposition.

Cardiovascular and Metabolic Conditions

The genetic variants in TNF-alpha pathway genes (TNFAIP3, TNIP1) that increase psoriasis risk also promote systemic inflammation that affects the cardiovascular system. Genome-wide studies have found genetic correlations between psoriasis and coronary artery disease, type 2 diabetes, and metabolic syndrome — suggesting shared underlying biology, not merely shared risk factors. This genetic connection reinforces why cardiovascular health monitoring is an important part of psoriasis care.

Genetic Risk vs Destiny: What You Can Control

Perhaps the most important message in this entire article is this: having psoriasis genes is not the same as being destined to have psoriasis. And having psoriasis — regardless of your genetic background — means you have genuine power over its severity, frequency, and long-term trajectory through the choices you make every day.

What the Genes Do and Do Not Control

Your genes set the immunological context — the threshold at which your immune system responds to triggers, the specific cytokines it produces in excess, the efficiency of your skin barrier, and the sensitivity of your T-cells to self-antigens. They do not determine whether that immune dysregulation will actually be triggered in your lifetime. They do not control how you eat, whether you smoke, how you manage stress, whether you treat infections promptly, or whether you seek medical care early. All of these non-genetic factors remain within your sphere of influence.

Evidence-Based Lifestyle Modifications That Modify Genetic Risk

Clinical research has identified several lifestyle interventions with documented effects on psoriasis severity that operate independently of genetic risk — meaning they are beneficial regardless of which genetic variants a person carries:

Weight management: Obesity amplifies psoriatic inflammation through pro-inflammatory adipokines. Clinical trials have shown that weight loss alone — without any medication change — can produce PASI score reductions of 40–50% in overweight and obese psoriasis patients. Weight loss also improves response to systemic and biologic therapies.

Smoking cessation: Smoking is causally linked to psoriasis through epigenetic mechanisms as well as direct immune effects. Stopping smoking is associated with progressive improvement in psoriasis severity over 12–24 months and is particularly impactful for palmoplantar pustulosis, where smoking is considered a near-essential cofactor.

Alcohol reduction: Heavy alcohol use promotes systemic inflammation, reduces treatment response, and is independently associated with more severe psoriasis. Even moderate reduction in alcohol consumption has been shown to improve psoriasis control — and is particularly important for patients on methotrexate, given the combined hepatotoxicity risk.

Stress management: Since psychological stress directly activates the same immune pathways that are genetically amplified in psoriasis, stress reduction — through yoga, mindfulness-based stress reduction (MBSR), cognitive behavioural therapy, or exercise — produces measurable reductions in psoriasis activity. Studies have shown that patients who engage in stress management programmes alongside medical treatment achieve significantly better outcomes than those on medication alone.

Anti-inflammatory diet: Dietary patterns influence cytokine production, gut microbiome composition, and systemic inflammatory markers — all relevant to psoriasis. Mediterranean-style diets, rich in omega-3 fatty acids, fresh vegetables, and whole grains, are associated with lower psoriasis severity scores in multiple observational studies. For Indian patients, limiting high-glycaemic-index foods, processed snacks, and excessive red meat while increasing oily fish, leafy greens, and turmeric-containing foods can produce meaningful improvements.

Natural and Plant-Based Treatments That Work With Your Genetics

Well-formulated plant-based treatments target the inflammatory pathways that are genetically amplified in psoriasis — not by genetic editing, but by modulating how those pathways express themselves. Curcumin inhibits NF-kB (a transcription factor that drives the overexpression of TNF-alpha and IL-6 seen in genetically susceptible patients). Neem compounds suppress Th1/Th17 cytokine production. Bakuchi (Psoralea corylifolia) inhibits keratinocyte hyperproliferation through a psoralen-based mechanism.

These are not genetic interventions, but they are working at the level of gene product activity — modulating the functional expression of the immune pathways that genetics has made more active. This is why evidence-backed Ayurvedic formulations can have clinically meaningful effects in psoriasis even at the genetic level of the disease.

Should You Get Genetic Testing for Psoriasis?

With genetic testing becoming increasingly accessible and affordable, many people with psoriasis — or with a strong family history — wonder whether a genetic test can predict their risk or guide their treatment. The current answer is nuanced.

What Genetic Testing Can and Cannot Tell You

As of 2026, no clinically validated genetic test exists that can reliably predict whether an individual will develop psoriasis or how severe their disease will be. While HLA-Cw6 testing is technically possible and is used in some research settings, the positive predictive value of HLA-Cw6 alone is low — the majority of HLA-Cw6 carriers never develop psoriasis. The polygenic nature of psoriasis means that a complete genetic risk picture would require testing dozens of loci simultaneously and integrating the results in ways that have not yet been validated for clinical use.

Pharmacogenomics — using genetics to guide treatment choice — is an active area of research in psoriasis. There is early evidence that HLA-Cw6 status influences response to certain biologics (patients who are HLA-Cw6 positive appear to respond particularly well to ustekinumab in some studies). If this evidence matures into clinical practice, genetic testing could eventually guide biologic selection. But this remains a research frontier rather than the current clinical standard of care.

Practical Advice for Families

If psoriasis runs in your family, the most useful steps are not genetic testing but clinical vigilance. Know the early signs of psoriasis — red, scaly, itchy patches on the scalp, elbows, knees, or lower back; nail pitting or discolouration; joint pain alongside skin symptoms. Seek dermatological evaluation early rather than waiting for symptoms to become severe. And put in place the lifestyle foundations — healthy weight, stress management, anti-inflammatory diet, no smoking — that reduce environmental risk regardless of what your genes say.

Conclusion: Your Genes Are a Starting Point, Not a Final Verdict

Psoriasis is significantly genetic — that much is established and clear. More than 80 gene loci influence psoriasis risk, identical twins show strong but incomplete concordance, and families with affected members carry measurably elevated risk. But none of this makes psoriasis inevitable, uncontrollable, or untreatable. What your genes determine is a predisposition — a biological context in which psoriasis is more likely to develop if and when the right environmental triggers arrive.

The science of epigenetics has made it clear that how your genes behave is partly within your control — shaped by the food you eat, the stress you carry, the lifestyle choices you make, and the treatments you pursue. For people with a family history of psoriasis, the most useful response to that knowledge is not anxiety about genetics but action on the modifiable factors: managing weight, stress, triggers, and skin care proactively, and working with a dermatologist who understands the full picture of the condition.

Frequently Asked Questions: Is Psoriasis Genetic?

Q1. Is psoriasis inherited from the mother or the father?

Psoriasis can be inherited from either parent — or both. The genetic risk comes from multiple gene variants distributed across many chromosomes, not from a single maternal or paternal gene. Studies have not found a significant difference in psoriasis risk based on which parent is affected. If both parents have psoriasis, the risk for each child is substantially higher than if only one parent is affected, regardless of which parent carries more risk variants.

Q2. My parents don't have psoriasis — why do I?

Psoriasis can appear without any family history for several reasons. First, the condition is polygenic — each parent may carry some risk variants without having enough to cross the threshold for disease themselves, but their combination in a child may produce a higher-risk genetic profile. Second, family members may have very mild or undiagnosed psoriasis. Third, your particular combination of environmental triggers — a significant infection, a period of severe stress, a medication — may have been sufficient to activate a pre-existing but previously dormant genetic predisposition.

Q3. If I have psoriasis, what is the risk for my children?

With one parent affected, each child has approximately a 10% lifetime risk of developing psoriasis — compared to the general population risk of 2–3%. This means that approximately 90% of children of one affected parent will not develop psoriasis. If both parents are affected, the risk rises to 40–70%. These are population averages; individual risk depends on which specific genetic variants are involved and on the environmental and lifestyle factors each child encounters.

Q4. Is there a genetic test for psoriasis?

No validated clinical genetic test currently exists for diagnosing psoriasis or reliably predicting who will develop it. While HLA-Cw6 testing is available and is used in some research settings, its predictive value in isolation is too low for routine clinical use. Psoriasis is diagnosed clinically, by a dermatologist examining the skin, rather than through genetic testing. Pharmacogenomic testing to guide biologic selection is an area of active research but has not yet reached standard clinical practice.

Q5. Can you prevent psoriasis if it runs in your family?

You cannot change your genes, but you can significantly modify your risk. Maintaining a healthy weight, not smoking, limiting alcohol, managing stress through regular exercise and mindfulness, eating an anti-inflammatory diet, protecting your skin from injury, and treating infections promptly are all evidence-backed strategies for reducing the likelihood of psoriasis onset — or the frequency and severity of flares if psoriasis has already developed. Genes set the context; lifestyle shapes the outcome.

Q6. Is early-onset psoriasis more genetic than late-onset?

Yes — Type I psoriasis (onset before age 40) is more strongly associated with HLA-Cw6, has a stronger family history, and is generally more severe than Type II psoriasis (onset after age 40). Late-onset psoriasis is less strongly linked to specific genetic variants and is more likely to be triggered primarily by environmental factors — medications, infections, or significant life stressors — in individuals with a modest genetic predisposition.

Q7. Does psoriasis skip a generation?

It can appear to. Because psoriasis is polygenic — influenced by many genes each with small effects — the combination of risk variants that produces disease may not be assembled in every generation. Parents may each carry some risk variants without crossing the threshold for disease themselves, but a child who inherits particular combinations from both parents may have a higher total genetic load. Alternatively, a generation may escape the environmental triggers that would have activated their genetic predisposition. Skipping generations does not mean the genetic risk disappears; it means the full expression of risk did not occur in that generation.

Q8. Is psoriatic arthritis also genetic?

Yes — psoriatic arthritis shares many of the same genetic risk factors as psoriasis, including HLA-Cw6, IL23R variants, and TNFAIP3. It also has additional genetic risk factors, including HLA-B27, which is particularly associated with axial (spinal) involvement. If you have psoriasis and a family history of psoriatic arthritis, monitoring for early joint symptoms — pain, stiffness, swelling, particularly in the morning — is important, since early treatment significantly improves long-term joint outcomes.

Q9. Can epigenetics reverse genetic psoriasis risk?

Epigenetics cannot rewrite your DNA, but it can influence how your psoriasis-associated genes behave. Lifestyle changes — quitting smoking, reducing alcohol, eating an anti-inflammatory diet, managing stress, achieving a healthy weight — produce measurable epigenetic changes that reduce the expression of pro-inflammatory genes. This is a genuine mechanism, not just wellness advice. Research on discordant identical twins has shown that the twin without psoriasis has systematically different epigenetic profiles at key immune gene loci — suggesting that epigenetic management of genetic risk is a real possibility.

Q10. Will my psoriasis get worse over time because of my genetics?

Genetics alone does not determine whether psoriasis worsens over time. The course of psoriasis is highly individual and shaped by a combination of genetic factors, treatment adherence, lifestyle, comorbidities, and trigger management. Many people with strong genetic predisposition achieve long periods of remission with appropriate treatment and lifestyle modification. Conversely, people with modest genetic risk may have severe, treatment-resistant psoriasis if their environmental triggers are unmanaged. Taking an active role in management — with a dermatologist's guidance — is the single most important determinant of long-term outcome.

Sources and References

•       Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526.

•       Duffin KC, et al. The genetics of psoriasis and psoriatic arthritis. Dermatol Clin. 2015;33(1):1–11.

•       Tsoi LC, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–1348.

•       Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kB pathways. Nat Genet. 2009;41(2):199–204.

•       Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.

•       Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315.

•       Elder JT, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol. 2001;137(11):1447–1454.

•       Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet. 1998;7(10):1537–1545.

•       Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–321.

•       Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.

•       Farber EM, Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.

•       Menter A, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.

•       Budu-Aggrey A, et al. Evidence of a causal relationship between body mass index and psoriasis. PLOS Med. 2019;16(1):e1002739.

•       Naldi L, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis. J Invest Dermatol. 2005;125(1):61–67.

•       Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.

•       Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities. Indian Dermatol Online J. 2016;7(6):471–480.

•       Suárez-Fariñas M, et al. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131(2):391–400.

•       National Psoriasis Foundation. Causes and Triggers. www.psoriasis.org (accessed 2024).

•       World Health Organization. Global Report on Psoriasis. Geneva: WHO; 2016.

•       IADVL Psoriasis Task Force. Indian guidelines for the management of psoriasis. Indian J Dermatol Venereol Leprol. 2020.

Last reviewed: June 2025. This article is for informational purposes only and does not substitute for professional medical advice. Always consult a qualified dermatologist for diagnosis and personalised care.